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TERT promoter mutations were recently discovered in melanoma by next generation sequencing. Subsequently,
several malignancies including urothelial carcinoma were also found to be associated with the same TERT promoter
mutations. Small cell carcinoma (SCC) of the urinary bladder is a rare subtype with an aggressive clinical course.
Despite the frequent occurrence of TERT promoter mutations in urothelial carcinoma, the incidence of the
mutations in SCC of the urinary bladder is unknown. In addition, as a potential molecular marker to distinguish SCC
of the urinary bladder from SCC of the prostate, lung (SCLC) and other origins, this information may be clinically
useful. We collected a total of 11 cases of SCC of the urinary bladder (10 cases are primary SCC of the urinary
bladder; 1 case has primary SCC of the urinary bladder and liver metastasis). We also included 20 cases of SCLC, 2
cases of SCC of the prostate, 5 cases of Merkel cell carcinoma, and 6 cases of SCC from other sites (cervical, GE
junction, breast, and soft tissue). In addition, 3 cases of non-neoplastic tissue from the matched SCC of bladder
patient and 14 cases of benign urinary bladder were also included. All tumor sections have been examined to
confirm the diagnosis and to make sure more than 20% are of tumor content. Genomic DNA was isolated from
FFPE tissue and a fragment of the TERT promoter (145 bp) was amplified by PCR. The TERT promoter mutations
are determined by bi-directional Sanger sequencing. All (11/11) SCC of the urinary bladder bear TERT promoter
mutation C228T. Neither of SCC from all other origins nor matched non-neoplastic tissue contains the TERT
promoter mutations. We demonstrated a high frequency TERT promoter mutation in SCC of the urinary bladder,
but not in SCC of other origin, such as the prostate. The findings further illustrate molecular differences between
SCC of the urinary bladder and SCC of other origins, despite their shared morphologic and immunophenotypic
similarities. The TERT promoter mutation may be a biomarker differentiating SCC of the urinary bladder from SCC
of other origins.Introduction
Small cell carcinoma (SCC) is a distinct clinicopathologic
entity that usually originates from the lung but can also
arise in almost any extrapulmonary sites. Extrapulmonary
small cell carcinomas (ESCCs) are rare, and have been de-
scribed most frequently in the urinary bladder, prostate,
esophagus, stomach, colon and rectum, gallbladder, larynx,
salivary glands, cervix, and skin. Small cell carcinoma
of the bladder is a rare, aggressive, poorly differentiated* Correspondence: zhongm@wcmc.com
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carcinoma of the lung in clinical behavior. In fact, bladder
small cell carcinoma is frequently found in conjunction
with conventional urothelial carcinoma and/or other
histologic variants: squamous and glandular differenti-
ation. Small cell carcinoma of the prostate is also an un-
usual and aggressive subtype, only accounting for 0.5–2%
of all prostate cancers [1]. Approximately 50% of the time,
prostatic small cell carcinoma occurs in the background of
usual-type acinar carcinoma and the two components may
be intermingled, thus suggesting a common origin. These
phenomena strongly suggest that different SCC may
originate from cells of different primary sites. DisregardingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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not identical, histopathological morphology and immuno-
phenotype. In addition, small cell carcinoma will occasion-
ally be present with metastatic disease. In this scenario,
primary site is difficult to define by tumor morphology
and IHC stains.
Small cell carcinoma is currently classified as a discrete
entity and the same chemotherapy regimens are used in
all small cell carcinoma. Exploring the origin of different
SCCs may help us understand the carcinogenesis of this
aggressive tumor and contribute to a specific target ther-
apy. Acutely, molecular studies have indicated that small
cell carcinoma of urinary bladder and usual types of
urothelial cancer are derived from the same clonal popula-
tion. In addition, up to 50% of small cell carcinoma of
prostate carries ERG translocation, which is commonly
seen only in prostate acinar carcinoma [2]. These evidence
suggest that at least part of small cell carcinoma of blad-
der and prostate are not de novo and may be derived from
usual-types of urothealial carcinoma and prostatic acinar
adenocarcinoma, respectively.
Telomerase reverse transcriptase (TERT) activities are
frequently upregulated in many human cancers, and are
thought to be an important mechanism contributing to
human tumorigenesis [3]. Recently, two studies reported
[4,5] a high frequency (approximately 70%) somatic muta-
tion in the TERT promoter in melanoma at positions
1,295,228 (C228T) and 1,295,250 (C250T). These muta-
tions create consensus binding motifs for E-twenty six
(ETS)/ternary complex factor (TCF) transcription factors
(GGA[A/T] or CCGGAA), leading to increased TERT pro-
moter activity. Subsequently, theses mutations have been
found to be associated with different types of cancer, in-
cluding urothelial carcinoma, but not in other common
carcinoma, such as: lung, prostate, breast and cervical
cancers [6]. However, there is no report about the muta-
tion status in small cell carcinoma of the bladder, prostate,
lung or other origins. In this study, we investigated TERT
promoter mutations in small cell carcinoma of the blad-
der, prostate, lung and other primary sites.
Materials and methods
After IRB (WMC, L-10,884 by New York Medical College)
approval, the following cases were collected for this study:
20 cases of SCLC (including 3 metastases); 11 cases of
SCC of the urinary bladder (including primary SCC of the
urinary bladder from 10 patients, one patient with both
primary and liver metastasis), 14 cases of normal urinary
bladder tissue. 2 cases of prostatic small cell carcinoma; 5
cases of Merkel cell carcinoma; 2 cases of small cell car-
cinoma from cervix; 1 case of small cell carcinoma from
breast; 1 case of small cell carcinoma from GE junction
and 2 cases of small cell carcinoma from soft tissue. H&E
sections were reviewed by board-certified pathologists toconfirm the diagnosis and ensure that ≥20% of the cells
used for DNA purification were neoplastic. Genomic
DNA from tissues was isolated by using standard proce-
dures of protease K digestion, QIAGEN kit (QIAamp
DNA Mini). A fragment of the TERT promoter was ampli-
fied by polymerase chain reaction (PCR) using primers
5′-CAGCGCTGCCTGAAACTC-3′ (sense) and 5′-GTCC
TGCCCCTTCACCTT-3′ (antisense), resulting in a PCR
product of 163 bp, which contained the sites of C228T and
C250T mutations(chr5: 1,295,228; chr5: 1,295,250, respect-
ively; hg19). Amplification PCR was performed with an ini-
tial denaturation at 94°C for 5 min, followed by 40 cycles of
97°C denaturation for 30 sec, 55°C annealing for 30 sec and
68°C elongation for 30 sec. Quality of PCR products was
confirmed by gel electrophoresis. Sequencing both strands
was performed by using a BigDye terminator v1.1 cycle se-
quencing kit (Applied Biosystems) on ABI 3500xL genetic
analyzer (Applied Biosystems). The statistical analysis was
performed by SPSS 16.0 software. Rates of mutation were
compared using chi-square test and Fisher’s exact tests
among groups. A P value less than 0.05 was considered as
statistically significant.
Results
Among all 11 cases of SCC of the urinary bladder evalu-
ated for TERT promoter mutation, 2 were radical cystec-
tomy, 2 were transurethral resections of bladder tumor
(TURBT), 5 were bladder tumor biopsy and 1 was with
both partial cystectomies and metastatic biopsy from liver.
The average patient age was 75 years (range: 53–88), with
6 males and 4 females. Almost all primary cases showed
additional non-SCC components including: usual urothe-
lial carcinoma, carcinoma with squamous or glandular dif-
ferentiation. After PCR and sequencing, TERT C228T
mutation was identified in all 11 cases (100%) of bladder
SCC (Figure 1). The non-neoplastic tissue from 3 cases
with separate normal tissue blocks did not show TERT
promoter mutation (0/3). All cases with benign urinary
bladder tissue have no TERT promoter mutation (0/14).
This confirmed that TERT promoter mutation is a high
frequency genetic alteration in SCC of bladder and it is
somatic. None of SCC of the urinary bladder is GATA-3
positive by immunohistochemistry staining.
In 20 SCLC cases, 3 (15%) were wedge resections, 14
(70%) were lung biopsies, 2 (10%) were metastases liver
biopsy, and 1 (5%) was metastasis in adrenal gland. The
average patient age was 68 years (range: 56–82), with
9 males and 11 females. None of these cases of SCLC
(0/20), including metastases of liver or adrenal, showed
no TERT promoter mutation.
In 2 prostate small cell carcinomas, one was from pros-
tatic needle biopsy which showed 3 of 12 cores con-
tained SCC; the other one was from a bladder neck
lesion biopsy from a patient who had a prostatomy
Figure 1 TERT promoter mutations in SCC of urinary bladder cancer. Shown are representative sequence of the wild-type TERT promoter
and TERT promoter mutation as indicated for bladder cancer. The upper portion of the figure shows the sense sequences of the wild-type DNA
and the nucleotide changes of C228T mutation. The lower portion of the figure shows the antisense sequences of the wild-type DNA and the
nucleotide changes of the G228A mutation.
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was identified in neither case.
In small cell carcinoma from other origins, including 5
cases of Merkel cell carcinoma, 2 case from cervix; 1
case from breast; 1 case from GE junction and 2 cases
from soft tissue in extremities, no TERT promoter muta-
tion was identified in all of these cases (Table 1).Table 1 TERT promoter mutation in SCC of different
origins (Chi-Square Tests P < 0.05)
Location TERT promoter mutation
SCC of Lung 0% (0/20)
SCC of Bladder 100% (11/11)
Counterpart normal tissue of above case 0% (0/3)
Benign urinary bladder tissue 0% (0/14)
SCC of Prostate 0% (0/2)
Merkel cell carcinoma 0% (0/5)
Other origins (breast, extremities,
JE junction, Cervix, etc.)
0% (0/6)Discussion
Small cell carcinoma (SCC) most commonly arises in the
lower respiratory tract of chronic smokers and is usually
rapidly evolving and lethal. It is rare for SCC to arise in
extra pulmonary sites which including urinary bladder
and prostate. Histologic criteria for the diagnosis of extra-
pulmonary SCC are the same as those for pulmonary
SCC. The tumor usually has a patternless type of diffuse
growth, whereas occasionally and focally, nests and
trabeculae are observed. The tumor cells have sparse
cytoplasm and consequently exhibit nuclear crowding andmolding. Nucleoli are often inconspicuous, and the chro-
matin is finely stippled (salt-and-pepper). Frequent mi-
toses, crush artifact, geographic necrosis, and Azzopardi
effect are seen. In addition to morphological similarity, no
immunohistohistochemical (IHC) marker(s) can reliably
differentiate SCC among lung, prostate, bladder or other
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42% (21 of 50) of extrapulmonary SCC cases, including
prostate and urinary bladder (1/3 each) primaries. A series
44 cases of SCC of the urinary bladder cases study also
showed: TTF-1+, 11 (25%); synaptophysin+, 22 (50%) [8].
TTF-1 is often positive in prostate small cell carcinomas
[9,10]. Prostate-specific immunostains (such as PSA, p501s
and PSMA) are positive in only a minority of small cell car-
cinoma (approximately 20–25%) [10,11] AR and NKX3-1
were not expressed in the majority of small cell carcinoma,
although the majority of the concurrent acinar foci were
positive for these markers [2]. Therefore, it is almost impos-
sible for pathologists to determine the origin by SCC by
morphology and IHC stains.
Despite their shared histologic morphologies and IHC
profiles, some evidence suggest that SCC is not de novo
and arise from usual type of carcinoma at different
primary sites. First of all, SCCs are more frequently
admixed with other histologic subtype(s). In fact, almost
all SCC of bladder cases in our study demonstrated
additional non-SCC components: frequently high grade
urothelial carcinoma, as well as squamous and/or glan-
dular differentiation. All SCC of lung cases in this study
did not show additional usual carcinoma, perhapsdue to
small tissue of biopsy. One of two prostatic SCCs had
previous prostatic acinar adenocarcinoma, Gleason score
4 + 3. Additionally, molecular genetic studies have also
suggested a common clonal origin for bladder SCC and
coexisting bladder UC [12,13]. X chromosomal inactiva-
tion analysis [12] in females illustrated the same nonran-
dom inactivation in both SCC of the urinary bladder and
usual UC. Identical point mutations of TP53 were found
in invasive SCC of the urinary bladder and coexisting
UC in situ; further more, no loss of heterozygosity of 9
microsatellite markers and TP53alu was found in either
component [13]. In prostatic SCC, it has been found that
ERG rearrangements in nearly half of SCC of the pros-
tate is a similar rate of the same rearrangements in pros-
tatic acinar carcinomas; and these rearrangements have
not been detected in SCC of the urinary bladder or lung
[2]. It has been well established that Merkel cell virus
is strongly associated with only Merkel cell carcinoma,
but not SCC of any other origins. Recent reports [14,15]
also revealed that small cell carcinoma of the ovary, hy-
percalcemic type, displays frequent inactivating germline
and somatic mutations in SMARCA4, and this mutation
is very rare in other common tumors. All of these evi-
dence strongly suggest that despite large overlapping of
morphology and immunophenotype, SCC from different
origins may not have the same oncogenesis at molecular
level. Different type of SCC may need specific treatment
and management.
TERT promoter mutations, originally be discovered in ~70%
melanoma, have also been found to be the most commongenetic mutations of UC. Interestingly, these mutations
have very low incidence in other prevalent carcinomas:
lung, prostate and colon cancers. This phenomenon pro-
motes us to evaluate TERT promoter mutations in SCC of
different origins. Our data showed that no TERT pro-
moter mutations were identified in SCC of lung, prostate
and other origins, in contrast, all SCC of bladder harbor
TERT promoter mutation: C228T. These incidences of
TERT promoter mutations in SCC of different origins
are concord with those counterpart usual carcinomas.
Multiple studies [16-18] including our unpublished results
demonstrated that up to 70-80% UC carries the TERT
promoter mutations disregarding grade, stage or location.
This study showed 100% SCC of bladder carry TERT pro-
moter mutation: C228T. Additionally, no C250T TERT
promoter mutation, the second most common mutation
in UC, is identifies in SCC of bladder. The difference may
partly due to relative small number cases (10) of SCC
bladder, but the difference is statically significance. To
confirm and understand the biological meaning of this
difference, larger case number studies are required.
Interestingly, the tumors from both primary and liver
metastasis of SCC bladder demonstrated the same muta-
tion. This further supports that TERT promoter mutations
can be used as a SCC bladder marker to determine the
primary site of metastatic SCC. Since low frequency to
none of TERT promoter mutations are in SCC of lung,
prostate and other sites, only positive mutation could be
suggestive of bladder origin. The negative mutations could
be unfavored bladder origin, but could not be used to dis-
tinguish among other origins. The studies of using TERT
IHC stain as a surrogate test for TERT promoter muta-
tions are few and results are controversial. TERT expres-
sion upregulation is very common in many tumors and
probably is caused by different molecular mechanisms.
These mutations create consensus binding motifs for
E-twenty six (ETS)/ternary complex factor (TCF) tran-
scription factors (GGA[A/T] or CCGGAA) leading to
increased TERT promoter activity and subsequently TERT
transcriptional upregulation. Presumably, TERT IHC stain
can detect TERT expression upregulation. However, TERT
expression upregulation could not be distinguished be-
tween TERT promoter mutations and other molecular
mechanisms, such as gene amplification. TERT promoter
mutations in urothelial bladder cancer are not associ-
ated with TERT mRNA levels [17]. Thus, molecular
method is still the only reliable approach to detect TERT
promoter mutations.
In summary, we reported high frequency TERT pro-
moter mutation in SCC of bladder, but not in SCC of
other origins. This further illustrated the heterogeneity
of SCC at molecular level and provided an addition piece
of evidence that origination of SCC bladder may be as
the same as that of usual urothelial carcinoma. Most
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potential biomarker for bladder small cell carcinoma.
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